SG9999014716 - Common Stock
WAVE LIFE SCIENCES LTD
NASDAQ:WVE (7/2/2024, 7:00:03 PM)
After market: 5.18 -0.04 (-0.77%)5.22
-0.02 (-0.29%)
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. The company employs 250 full-time employees The company went IPO on 2015-11-11. The firm is engaged in developing medicines across multiple therapeutic modalities using PRISM, its proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. The Company’s ribonucleic acid (RNA)-targeting oligonucleotides is designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. Its lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (DMD); liver, including alpha-1 antitrypsin deficiency (AATD); and the central nervous system (CNS), including Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These programs include WVE-N531, WVE-006, WVE-003, and WVE-004.
WAVE LIFE SCIENCES LTD
7 Straits View, #12-00, Marina One East Tower
Singapore 018936
P: 6562363388
CEO: Paul B. Bolno
Employees: 250
Website: https://www.wavelifesciences.com/
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo,...
Here you can normally see the latest stock twits on WVE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: